Previous close | 44.72 |
Open | 45.54 |
Bid | 48.04 x 400 |
Ask | 48.18 x 600 |
Day's range | 45.09 - 48.29 |
52-week range | 4.82 - 48.29 |
Volume | |
Avg. volume | 1,552,379 |
Market cap | 5.188B |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.96 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 61.56 |
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on July 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 128,200 shares of its common stock and 22,100 restricted stock units ("RSUs") to six (6) new non-executive employees under the Avidity Bioscien
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is partnering with the FSHD Society and joining the global community of patients, caregivers, and healthcare providers to raise awareness of facioscapulohumeral muscular dystrophy in support of World FSHD Day. The FSHD Society is hosting a webinar with Avidity today at 1:00 p.m. ET to share recent unpre
Key Insights The projected fair value for Avidity Biosciences is US$46.34 based on 2 Stage Free Cash Flow to Equity...